Vendor Intelligence Report: Welon Peptide Solutions

Executive summary

Across 38 Finnrick lab tests, Welon Peptide Solutions records 28 pass and 10 fail, an overall pass rate of 74%. The signal is uneven, not uniformly bad: Tirzepatide is the cleanest directional positive, TB-500 is fail-heavy, and Retatrutide plus GHK-Cu look better cumulatively but carry severe fill-control outliers. The methodology view matters here because wider pass thresholds can flatter a risky dosing history.

Welon's public accountability surface is thin. The site presents a China-facing peptide factory while vendor metadata lists the location as US; filings and site captures instead point to a late-2025 UK company at a mass-registration address, a Hong Kong contact address consistent with virtual-office use, and no older archive trail supporting a long operating history.

Documentation and recourse are the sharper buyer issues. A product-page COA set includes a product mismatch, vendor-signed certification, and manufacturer names not found in searched registries; field notes also show widespread missing batch IDs. Checkout used PayGate.to crypto settlement, where payments are final and non-disputable. The report follows how those controls intersect with the Welon-to-Lumira/Peptaura channel split and unverified off-site contact handles.

Inside the full report:

• Appendix A with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all six products
• Dated evidence timeline covering peptidecube.com WHOIS, zero Wayback history, ANTIET LTD incorporation, and Finnrick testing milestones
• Corporate filings for ANTIET LTD, Fei Li, the Shelton Street registered office, and the Hong Kong address
• COA-integrity review of captured certificate images, traceability gaps, and manufacturer-name checks
• Payment-stack analysis of WooCommerce and PayGate.to crypto settlement with buyer-recourse implications
• Welon, Lumira, Peptaura, Reddit, WhatsApp, and Telegram channel-verification map

Risk assessment

• Retatrutide dosing-inaccuracy risk — high: Finnrick records include a Retatrutide 15mg-labeled batch measured at 21.7mg (+44.7% overfill), creating dose-calculation risk despite a stronger cumulative rating.
• GHK-Cu dosing-inaccuracy risk — high: Finnrick records include a GHK-Cu 50mg-labeled batch measured at 15.9mg (-68.2% underfill), showing severe fill-control failure.
• TB-500 quality/reliability risk — high: TB-500 is fail-heavy in Finnrick testing: 5 tests, 1 pass and 4 fail, with a Finnrick rating of 30.53%.
• HGH quality/reliability risk — high: HGH is split in Finnrick testing: 4 tests, 2 pass and 2 fail, with a Finnrick rating of 45.72%.
• COA-integrity and batch-traceability risk — high: BPC-157 COAs on peptidecube.com are self-signed, include a Cagrilintide mismatch, and cite manufacturer names not found in searched registries; field notes also found 21 of 24 traced samples lacked batch IDs.
• Payment-recourse risk — high: Welon checkout used PayGate.to, whose FAQ says payments are final, instant and irreversible in USDC and customers cannot dispute payments.
• Brand-confusion and corporate-accountability risk — medium: Records tie the vendor to new UK entity ANTIET LTD at a mass-registration address, a Hong Kong virtual-office-style address, and a Lumira/Peptaura channel without authoritative official-channel verification.